This observation indirectly highlights the limitations of current single-agent anti-PD-1 therapy in HNSCC and implies that VPS25 could function as a potential molecular biomarker for predicting response to combination therapy. Here, PDCD1 is linked to head and neck squamous cell carcinoma.